Substituted thiadiazolesulfonamides
    1.
    发明授权
    Substituted thiadiazolesulfonamides 有权
    取代的噻二唑磺酰胺

    公开(公告)号:US06218412B1

    公开(公告)日:2001-04-17

    申请号:US09418026

    申请日:1999-10-14

    IPC分类号: C07D28508

    CPC分类号: C07D285/08

    摘要: Compounds of the formula (I): are suitable for the preparation of pharmaceuticals for prophylaxis and treatment of all those diseases where an increased concentration of interleukin-1&bgr; participates in their course, for example septic shock, leukemia, hepatitis, muscular degeneration, HIV infections or degenerative joint diseases (such as osteoarthrosis, spondylosis, chondrolysis following joint trauma or prolonged immobilization of joints following meniscus or patella injuries, or torn ligaments), diseases of the connective tissue (such as collagenosis, periodontal diseases, or wound-healing disturbances), and chronic diseases of the locomotor system (such as inflammatory or immunologically or metabolism-related acute and chronic arthritis, arthropathies, rheumatoid arthritis, myalgias and disturbances in bone metabolism).

    摘要翻译: 式(I)化合物适用于制备用于预防和治疗所有这些疾病的药物,其中白细胞介素-1β参与其过程的浓度增加,例如脓毒性休克,白血病,肝炎,肌肉退化,HIV感染 或退行性关节疾病(例如骨关节炎,椎关节强硬,关节创伤后的软骨溶解或半月板或髌骨损伤后关节的延长固定或撕裂的韧带),结缔组织的疾病(如胶原病,牙周病或伤口愈合障碍) ,以及运动系统的慢性疾病(例如炎性或免疫学或代谢相关的急性和慢性关节炎,关节病,类风湿性关节炎,肌肉痛和骨骼代谢紊乱)。

    Substituted thiadiazolesulfonamides
    2.
    发明授权
    Substituted thiadiazolesulfonamides 有权
    取代的噻二唑磺酰胺

    公开(公告)号:US06503934B2

    公开(公告)日:2003-01-07

    申请号:US09779823

    申请日:2001-02-09

    IPC分类号: C07D28508

    CPC分类号: C07D285/08

    摘要: Compounds of the formula (I): are suitable for the preparation of pharmaceuticals for prophylaxis and treatment of all those diseases where an increased concentration of interleukin-1&bgr; participates in their course, for example septic shock, leukemia, hepatitis, muscular degeneration, HIV infections or degenerative joint diseases (such as osteoarthrosis, spondylosis, chondrolysis following joint trauma or prolonged immobilization of joints following meniscus or patella injuries, or torn ligaments), diseases of the connective tissue (such as collagenosis, periodontal diseases, or wound-healing disturbances), and chronic diseases of the locomotor system (such as inflammatory or immunologically or metabolism-related acute and chronic arthritis, arthropathies, rheumatoid arthritis, myalgias and disturbances in bone metabolism).

    摘要翻译: 式(I)化合物适用于制备用于预防和治疗所有这些疾病的药物,其中白细胞介素-1β参与其过程的浓度增加,例如脓毒性休克,白血病,肝炎,肌肉退化,HIV感染 或退行性关节疾病(例如骨关节炎,椎关节强硬,关节创伤后的软骨溶解或半月板或髌骨损伤后关节的延长固定或撕裂的韧带),结缔组织的疾病(如胶原病,牙周病或伤口愈合障碍) ,以及运动系统的慢性疾病(例如炎性或免疫学或代谢相关的急性和慢性关节炎,关节病,类风湿性关节炎,肌肉痛和骨骼代谢紊乱)。